and disinfectants can inactivate virus particles and prevent viral transmission. It 27 has been previously demonstrated that bacteria or bacterial surface glycans can 28 enhance poliovirus virion stability and limit inactivation from heat or bleach. While 29 investigating the mechanisms underlying bacterial-enhanced virion thermal 30 stability, we identified and characterized a poliovirus mutant with increased 31 resistance to heat inactivation. This poliovirus mutant, M132V, harbors a single 32 amino acid change in the VP1 capsid-coding that is sufficient to confer heat 33 resistance. M132V was comparable to wild-type virus for replication in vitro, as 34 well as for replication and pathogenesis in orally-inoculated mice. Although the 35 M132V virus was stable in the absence of bacteria or feces at most 36 temperatures, M132V virus was stabilized by feces at very high temperatures. 37
Additionally, the M132V virus does not have enhanced stability during bleach 38 treatment, suggesting that thermal and bleach inactivation mechanisms are 39 separable. Our results suggest that different mechanisms underlie virion 40 stabilization by bacteria and the M132V mutation. Overall, this work sheds light 41 viruses. PV was incubated at 43°C in PBS for 6 h followed by quantification of 114 viable virus by plaque assay. Under these conditions, the infectivity of WT PV 115 was reduced by 99.99% compared to no heat treatment controls ( Figure 1A) . 116
Remaining viable viruses were amplified in HeLa cells followed by incubation at 117 43°C in PBS for 6 h. This cycle was repeated a total of 10 times. By passage 5 118 (P5), the heat exposed viruses had 2-fold increased viability after heat treatment 119 compared to the WT virus, and by passage 8 (P8), the heat-exposed viruses had 120 500-fold increased viability after heat treatment compared to the WT virus ( Figure  121 1A). After passage 10, we isolated RNA from the heat-passaged viruses, 122 performed reverse-transcriptase (RT)-PCR, and sequenced the capsid-coding 123 region. Sequence alignment revealed a single amino acid change, M132V in the 124 VP1 capsid protein ( Figure 1B) . The VP1-M132V mutation is buried inside the 125 capsid within the 8-stranded β-barrels of VP1 ( Figure 1C) . 126
127
A single amino acid change, VP1-M132V, is sufficient for thermal resistance 128
To confirm that the VP1-M132V mutation confers thermal resistance, we cloned 129 the M132V mutation into the PV infectious clone and examined viability by 130 plaque assay after incubation at 43°C for 6 h. As shown in Figure 1A , the M132V 131 amino acid change was sufficient to increase infectivity by more than 1000-fold 132 compared to WT PV. As a second method to quantify virion stability using a 133 physical/cell-free approach, we examined whether the M132V mutation alters 134 viral RNA release using a Particle Stability Thermal Release assay (PaSTRY) 135 (15) (12). Gradient-purified WT or M132V PV was mixed with SYBR Green andheated in a real-time PCR machine with fluorescence monitoring. SYBR Green 137 binds viral RNA upon release from capsids and can be used to determine the 138 temperature at which RNA release occurs. WT PV generated a peak of 139 fluorescence intensity indicating RNA release at 51°C (Figure 2) . However, for 140 M132V PV the fluorescence intensity peak shifted to 78°C (Figure 2) . Overall, 141 these data indicate that the M132V mutation in VP1 enhances viral stability by 142 limiting RNA release. 143
144

Replication of M132V and WT PV is equivalent in cultured cells and in mice 145
Because the M132V mutation can increase viral stability by delaying RNA 146 release during heat exposure and RNA release is critical for infection, we wanted 147 to determine if this mutant has a growth defect compared to WT PV. We first 148 compared the replication of M132V and WT PV in cell culture using single-cycle 149 growth curve assays. HeLa cells were infected at a multiplicity of infection (MOI) 150 of 10, and viral titers were determined over time by plaque assay. As shown in 151 Figure 3A , the M132V mutation did not significantly affect viral yields in HeLa 152 cells. Next we wanted to determine whether the M132V mutant has a fitness 153 defect in mice by examining viral shedding and pathogenesis in orally-inoculated 154 C57BL/6 PVR-IFNAR -/-mice. These mice express the human poliovirus receptor 155 (PVR) and are deficient for the interferon (IFN) α/β receptor (16), which confers 156 oral susceptibility to PV. Mice were orally inoculated with 10 8 PFU of either WT or 157 M132V PV, fecal samples were collected at 24, 48, and 72 hours post-inoculation 158 (hpi), and titers were determined by plaque assay. As shown in Figure 3B , wefound that fecal titers were similar for WT and M132V viruses, although M132V 160 titers were slightly lower than WT at 48 hpi. However, viral pathogenesis was 161 equivalent for WT and M132V PV ( Figure 3C ). Taken together, these results 162 suggest that the M132V mutation does not confer a major replication defect in 163 vitro or in vivo. 164
165
Feces can stabilize M132V PV at higher temperatures 166
Since PV spread by the fecal-oral route, virion stability in feces is important for 167 transmission to a new host. Previously we demonstrated that feces stabilize WT 168 PV (12). Because M132V PV has enhanced thermal stability, we suspected that 169 M132V virions do not require feces for stability in the environment. To examine 170 environmental stability of M132V and WT PV, we collected feces from uninfected 171 C57BL/6 PVR-IFNAR -/-mice, resuspended them in PBS, and incubated this 172 mixture with 10 5 PFU of M132V or WT PV at 37°C prior to quantification of viable 173 virus by plaque assay over several time points. As shown in Figure 4A , WT PV 174 was stabilized by feces over time, consistent with our previous findings that 175 bacteria or bacterial components in feces enhance virion stability (12, 13). In 176 contrast, M132V PV was stable even in the absence of feces, although fecal 177 components slightly increased virion stability of the mutant at a late time point 178 (day 8)( Figure 4A ). 179
Since we selected for the M132V mutant at 43°C, it was possible that 180 stability by fecal components was masked by the mutant's inherent stability at 181 37°C. To investigate this, we examined the stability of WT and M132V PV during 182 6 h incubations at higher temperatures in the presence or absence of feces. As 183 shown in Figure 4B , after 6 h incubation at 43°C in PBS, WT PV viability was 184 reduced >1000-fold whereas M132V PV viability was reduced <2-fold. Feces 185 stabilized WT PV up to an incubation temperature of 47°C. While M132V PV was 186 stable in PBS up to 47°C, exposure to feces allowed recovery of 20% viable virus 187 at 49°C and 1% viable virus at 51°C. Thus, for both WT and M132V viruses, 188 feces stabilized viruses at temperatures that are damaging to the virions. 189
190
WT and M132V PV have equivalent inactivation following bleach treatment 191
Hyper-stable virions could be dangerous to human health as they can persist 192 longer in the environment and potentially resist inactivation by disinfectants such 193 as bleach (12). Given that M132V PV is more thermostable than WT PV, we 194 wanted to determine if the mutant is resistant to bleach inactivation. We treated 195 resistance (8, 9). Ours is the first study to identify VP1-M132V as a stability 223 determinant, and neither VP1-V87A or VP1-I194V were selected during our heat 224 passage experiments. These results suggest that multiple amino acids in VP1 225 can contribute to heat resistance and that there are multiple paths to generate 226 heat resistant PV variants. 227
Our work has shown that bacteria and bacterial glycans limit inactivation 228 from both heat and bleach treatment, which led us to hypothesize that bacterial 229 glycans bind virions and limit virion conformational changes and "breathing" that 230 can lead to premature RNA release (12, 13). Although the specific binding site(s) 231 of bacterial components on viral capsids have not been identified, it is highly 232 likely that surface-exposed residues are involved. Importantly, M132V PV is not 233 defective in bacterial binding (Aguilera et al., accompanying manuscript), and 234 exposure to feces limits thermal inactivation of M132V PV at very high 235 temperatures (49°C/51°C, Figure 4B ). Thus, M132V PV does not require feces or 236 bacteria for stabilization at a wide range of temperatures, but can be stabilized by 237 feces at very high temperatures. 238
We originally sought virion stability mutants to gain insight into factors that 239 affect capsid stability and to probe mechanisms and consequences of bacterial-240 mediated virion stabilization. Two lines of evidence suggest that mechanisms of 241 stabilization by the M132V mutation and by bacteria/feces are different. First, if 242 the two stabilization mechanisms were the same, the mutant should not be 243 stabilized by bacteria or feces; however, the M132V mutant PV was stabilized by 244 feces at very high temperatures (49°C/51°C, Figure 4B ). This result suggests that 245 virion thermal stabilization by bacteria is separate from and stronger than virion 246 stabilization by the M132V mutation. Second, if the two stabilization mechanisms 247 were the same, the M132V mutation should confer bleach resistance to the same 248 extent as exposure to bacteria; however, the M132V mutant PV was as 249 susceptible as WT PV to bleach inactivation ( Figure 5 ). This result suggests that 250 virion bleach stabilization by bacteria and bacterial glycans is separate from 251 virion thermal stabilization by the M132V mutation. Overall our results suggest 252 capsid dynamics are complex and that multiple distinct mechanisms influence PV 253 stability and inactivation. 254
255
EXPERIMENTAL METHODS 256
Viruses and Cells 257
Serotype 1 Mahoney PV cell culture infections and plaque assays were 258 performed using HeLa cells as previously described (17). HeLa cells were 259 propagated in Dulbecco's modified Eagle's medium (DMEM) supplemented with 260 10% calf serum. Virus stocks from cellular lysates were derived from low 261 passage stocks. For PaSTRy experiments, PV stocks were CsCl-gradient 262 purified as previously described (13). 263
Selection, sequencing, and cloning of M132V PV 264
To select for thermal stable PV mutants, 10 6 PFU PV was incubated in PBS 265 supplemented with 100 μg/ml CaCl 2 and 100 μg/ml MgCl 2 (PBS+) for 6 h at 266
43°C. Remaining viable viruses were amplified using HeLa cells 12-16 h (until 267
cytopathic effects were visible. Sequential heating and amplification of viable 268 viruses was performed a total of 10 times. Viral RNA was isolated using TRIzol 269 as recommended by the manufacturer's protocol (Sigma) and cDNA covering the 270 capsid-coding region was synthesized using SuperScript II reverse transcriptase 271 Samples were heated from 25°C to 99°C on a 1% stepwise gradient with 296 fluorescent monitoring using the ABI 7500 real-time instrument (12). 297 298
Single-cycle growth curve assays 299
Six-well plates were seeded with 2x10 6 HeLa cells/well. Cells were inoculated 300 with either WT or M132V PV at a MOI of 10. After a 30 min incubation at 37°C, 301 the inoculum was aspirated from the cells. Cell monolayers were washed with 302 PBS and 3mL of fresh media was added. After 2, 4, 6, or 8 hpi at 37°C, cells 303
were washed with PBS, trypsinized, and pelleted. Cells were freeze-thawed three 304 times and the released intracellular viruses were quantified by plaque assay 305 using HeLa cells. 306
307
Mouse experiments 308
All animals were handled according to the Guide for the Care of Laboratory 309
Animals of the National Institutes of Health. All mouse studies were performed at 310 UT Southwestern (Animal Welfare Assurance #A3472-01) using protocols 311 approved by the local Institutional Animal Care and Use Committee in a manner 312 designed to minimize pain, and any animals that exhibited severe disease were 313 euthanized immediately. Four-to five-week-old female and C57BL/6 PVR-314 IFNAR -/-mice were orally inoculated with 10 8 PFU WT or M132V PV. Feces were 315 collected at 24, 48, 72 hpi and viral shedding in feces was quantified by plaque 316 assays. Survival of infected animals was also monitored for 12 dpi. Because PV 317 disease is progressive and irreversible in this system, mice were euthanized atthe first sign of disease, and these time points are shown in Fig. 3C . 319 320
Bleach inactivation assay 321
Bleach inactivation assays were performed as previously described (12). Briefly, 322
10
5 PFU of each virus was mixed with PBS+ and incubated at 37°C for 1 h. After 323 incubation, samples were processed in 0.0001% fresh bleach (diluted 324 immediately before the experiment) for 1 min. Bleach was neutralized by adding 325 equal volume of 0.01% sodium thiosulfate (Sigma). Plaque assays were 326 performed to determine amount of viable virus before and after treatment. 327
328
Statistical analysis 329
The differences between groups were examined by unpaired two-tailed Student t 330 tests. P< 0.05 was considered statically significant. WT and M132V mouse 331 survival curves were not significantly different (p>0.5 by log rank test Figure 3C) . 332
The differences among the groups in the fecal stability assays (Figure 4 
